NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 11589.90 -71.95 -0.62%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR)

 
AEGR Technical Analysis
4
As on 29th Nov 2016 AEGR Share Price closed @ 1.97 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.26 & Sell for SHORT-TERM with Stoploss of 2.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AEGR Share Price

Open 1.89 Change Price %
High 2.34 1 Day 0.10 5.35
Low 1.86 1 Week 0.00 0.00
Close 1.97 1 Month 0.00 0.00
Volume 2166128 1 Year 0.14 7.65
52 Week High 2.34 | 52 Week Low 1.75
 
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 45.49 2.52%
 
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
 
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
 
 
AEGR
Daily Charts
AEGR
Intraday Charts
Whats New @
Bazaartrend
AEGR
Free Analysis
 
AEGR Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE2.41
RESISTANCE2.23
SUPPORT1.71
SUPPORT1.53
SUPPORT0.00
SUPPORT0.00
 
AEGR Target for Month October
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
AEGR Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
AEGR Target for Year 2019
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
AEGR Other Details
Segment EQ
Market Capital 560309632.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.aegerion.com
 
AEGR Address
AEGR
101 Main Street
Suite 1850
Cambridge, MA 02142
United States
Phone: 617-500-7867
Fax: 617-945-7968
 
AEGR Latest News
 
Your Comments and Response on Aegerion Pharmaceuticals, Inc.
 
AEGR Business Profile
Aegerion Pharmaceuticals, Inc. (Aegerio), incorporated in February 2005, is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder called homozygous familial hypercholesterolemia (HoFH). The Company conducted a 78-week Phase III clinical trial of lomitapide in the treatment of adult patients with HoFH. The 56-week results of the trial were announced in May 2011. It completed the trial during the year ended December 31, 2011, and in January 2012, announced the 78-week results of the trial, which were consistent with the 56-week results. In 2011, the United States Food and Drug Administration (FDA) granted orphan drug designation for lomitapide in the treatment of HoFH. The Company’s lead product compound, lomitapide, is a small molecule microsomal triglyceride transfer protein (MTP), inhibitor (MTP-I), that the Company developed as an oral once-a-day treatment for patients with certain severe lipid disorders in 2011. Lomitapide has been evaluated in 14 Phase I and eight Phase II clinical trials, as well as the Phase III clinical trial completed in 2011. Approximately 940 patients have been treated with lomitapide as part of these clinical trials. As of December 31, 2011, it developed lomitapide as an oral, once-a-day treatment for patients with HoFH and familial chylomicronemia (FC).
 
© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service